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Over the last 30 years, conservative management of VTE has focused
mainly on the prevention of recurrent thrombotic events. The preven-
tion of long-term complications of venous thromboembolism (VTE),
such as post thrombotic syndrome (PTS), has gained less attention.
The quest for anticoagulant drugs that are equally effective as vitamin
K antagonists (VKAs) and that are easier to manage has concluded in a
favorable manner. For treatment of VTE, the non-vitamin K antagonist
oral anticoagulants (NOAC) are non-inferior to the VKAs with respect
to efficacy and are at least as safe if not safer. However, the NOACs do
not eliminate the risk of bleeding and gastrointestinal bleeding occurs
more frequently with some of the NOACs than with VKAs, particularly
in the elderly. This is an important issue because the risk of bleeding
makes long term anticoagulation for secondary VTE prevention less at-
tractive. To address this problem, efforts are underway to identify anti-
coagulants that are as effective as current treatments (VKAs andNOACs)
but produce less bleeding. Strategies that target factor XII or factor XI are
particularly promising and if agents can be identified that attenuate the
risk of thrombosis without affecting hemostasis, the issue of recurrent
thrombosis could easily be solved because patients could continue
therapy as long as needed, assuming there are no off -target side effects.
The risk of complications of DVT such as PTS, which occurs in 20-50% of
patients, is, amongst others, associated with poor early control of anti-
coagulant treatment and could possibly be reduced with more stable
levels of anticoagulation.⁎ Corresponding author at: Department of Internal Medicine, laboratory of Clinical
Thrombosis and Haemostasis, Maastricht University Medical Centre+, PO Box 616, 6200
MDMaastricht, The Netherlands.
E-mail address: arina.tencate@maastrichtuniversity.nl (A.J. ten Cate-Hoek).
http://dx.doi.org/10.1016/j.thromres.2015.07.036
0049-3848/© 2015 Published by Elsevier Ltd.2. Past Achievements
Antithrombotic therapy with VKAs is highly effective and has been
successfully used for over 60 years. The two major drawbacks of VKAs
are the risk of serious bleeding, such as intracranial bleeding, which
can occur even when the international normalized ratio (INR) is in the
therapeutic range, and the requirement for routine coagulation moni-
toring because of the numerous drug-drug and drug-food interactions.
These drawbacks were the incentive for the development of new anti-
coagulants that could be given in fixed doses without routine coagula-
tion monitoring and were safer than VKAs. The NOACs fulfill these
goals; they are easier to manage than VKAs, and are at least as effective
and produce less intracranial bleeding.
Long-term aspirin iswidely used for secondary prevention of arterial
thrombosis. Recently, aspirin has been compared with placebo for sec-
ondary prevention of VTE with the expectation that its benefit-to-risk
profile would make it an attractive alternative for patients unwilling
or unable to take VKAs long-term. A recent meta-analysis of two such
studies showed that compared with placebo, aspirin reduced the risk
of recurrent VTE by 32% and was associated with a low risk of bleeding.
The role of statins and contact activation inhibitors for prevention of
recurrent VTE remains to be established but initial clinical data are
promising.
The long-term complications of deep vein thrombosis (DVT) and
pulmonary embolism (PE), such as PTS and chronic thromboembolic
pulmonary hypertension (CTEPH), have been understudied. The Villalta
score is the preferred method for diagnosis of PTS, but there is room for
improvement. Although compression therapy was the mainstay for
prevention of PTS, a recent double blind trial found no effect with
early application of graded compression stockings. Nonetheless,
compression stockings continue to be used to manage PTS symptoms.
Studies into the pathophysiology of PTS have identified potential mech-
anisms, and further investigation is needed to determine whether this
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prevent this debilitating complication.
I. Role of Statins in venous thromboembolism (VTE)
[Harry R. Büller, Jossi S. Biedermann]
During 6–12 months of treatment with NOACs, the risk of recurrent
VTE is approximately 2% [1]. After stopping NOACs, the rate of recurrent
VTE at 6 and 12months is 6.2% and 10.7% respectively [2,3]. Hence, both
during and after anticoagulant therapy there is an unmet need to
further reduce the risk of recurrent disease. It is likely that targeting
other important biological pathways outside coagulation, most notably
the (vascular) inflammatory pathway, is most promising, particularly if
such interventions do not increase the risk of bleeding.
Statins have diverse effects, includingmodulation of almost all of the
components involved in thrombosis, i.e. platelets, endothelium, tissue
factor and other coagulation factors [4,5]. The net result of statin admin-
istration is invariably a reduction in thrombogenicity.
Numerous cohort studies [6] and population studies [7–9] suggest
that statin therapy may dose dependently reduce the risk of recurrent
VTE by 25-40%. There is only one randomized trial, which compared
rosuvastatin with placebo for primary VTE prevention in subjects with
increased levels of C-reactive protein [10]. Although the absolute rates
were low, this study reported a 43% reduction in VTE.
Capitalizing on developments in arterial thrombosis, we can expect
an explosion of clinical data with agents that target local and systemic
inflammation. These include old drugs like, methotrexate and colchi-
cine, as well as new agents that inhibit interleukin (IL)-1B, IL6, tumor
necrosis factor (TNF) and lipoprotein-associated phospholipase A2
[11]. The time has come in the VTE field to study drugs that control
inflammation both from a basic and a clinical perspective.
Consensus:
a. Current treatment for VTE needs improvement, mainly in secondary
prophylaxis.
b. The role of statins needs to be elucidated in clinical trials.
c. The ideal trial designwould be direct start in patients with a first un-
provoked VTE, with imbedded nested mechanistic studies
d. The best outcomemeasure is: recurrent VTE, but arterial events and
PTS should also be assessed as combined outcomes
e. As mono-therapy, statins should only be considered for secondary
VTE prevention in patients who refuse or cannot tolerate anticoagu-
lants or aspirin.
II. Aspirin for VTE prevention
[Karina Meijer, Minka Vries]
In recent years, the utility of aspirin for primary and secondary VTE
prevention has been studied in clinical trials and has become a subject
of heated debate. Concerning thromboprophylaxis after major orthope-
dic surgery, those who deem ‘fatal PE’ as the only relevant outcome fa-
vour aspirin. For this outcome, the Pulmonary Embolism Prevention
trial showed an advantage of aspirin over placebo [12]. Those who fa-
vour ‘all VTE’ as the outcome prefer low molecular weight heparin
(LMWH) over aspirin. The 2012 ACCP guidelines recommend all phar-
macological means, including aspirin, over no prophylaxis, but LMWH
was recommended over other agents (Grade 2B/2C) [13]. However,
interest was rekindled after Anderson et al. showed that after an initial
10-day course of LMWH, extended treatment with aspirin was non-
inferior to LMWH [14]. We discussed these data, and concluded that
further studies in this field are of low priority because there is no
unmet clinical need; LMWH and the NOACs offer safe, effective and
convenient means of prophylaxis.
For secondary prevention of VTE after a first non-provoked episode,
the combined results of theWARFASA and ASPIRE studies demonstrate
that comparedwith placebo, aspirin reduces the risk of recurrentVTE by
32% (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.51-0.90)[15]. However, the important question is how aspirin compares with
VKAs or NOACs to determine whether aspirin is a better option than
conventional or new anticoagulants. Direct comparisons are not avail-
able at this point– although a study comparing aspirinwith rivaroxaban
is ongoing – but a published network meta-analysis summarizes all of
the indirect evidence [16]. This evidencewas discussed, andwe reached
consensus that for themajority of patients, an anticoagulantwould offer
a better trade-off between efficacy and safety/convenience than aspirin.
A possible patient category thatwould benefit from aspirinwould be
those with a low-to-moderate risk of recurrence. Before studies into
these patient categories should be initiated, however, more precise
recurrence prediction tools are needed.
Three other interesting points were raised. First, the mechanism by
which aspirin prevents VTE is unknown. It is possible that the anti-
inflammatory or other protective effects of aspirin predominantly
occur when the endothelium is already damaged or activated, such as
after surgery or DVT. Second, because patients with cancer have platelet
hyper-reactivity [17], the role of aspirin in the pathogenesis of cancer-
associated VTE and its role for primary VTE prevention in cancer pa-
tients should be priorities. Third, patients often make choices that are
different from those expected by thrombosis experts. Discrete choice
experiments (DCE) are a powerful tool to determine which aspects of
antithrombotic therapy are important for patients not only regarding
acute, but also for chronic or even lifelong prevention strategies.
Multiple myeloma (MM) is one of the highest-risk cancers for VTE,
and treatment with immune-modulatory drugs further increases the
risk. Historically, aspirin is used for primary VTE prevention in such pa-
tients and is recommended in the guidelines [18,19]. Indeed, a Cochrane
review found a non-significant 49% reduction in the risk of VTE with
LMWH comparedwith aspirin(HR, 0.51; 95% CI,0.22-1.17) [20]. Howev-
er, recent observational cohorts, including the Melisse study, showed
high rates of VTE with current clinical practice [21]. In this setting,
formal studies comparing aspirin with anticoagulant drugs are a priority.
Consensus:
a. There is no clinical need for further studies of aspirin in primary
prevention of VTE in orthopaedic surgery
b. The role of aspirin in primary prevention of VTE in cancer patients
should be prioritized
c. In patientswithmultiplemyeloma,we need RCTs comparing aspirin
with anticoagulant drugs.
d. Studies of aspirin for secondary prevention should focus on patients
with low-to-moderate risk of recurrent VTE, more precise prediction
tools are needed before such studies can be initiated
e. More data are needed on the aspects of antithrombotic therapy that
are important for patients
III. New Oral Anticoagulants for VTE treatment; which patients,
which drug and which dose
[Y. Whitney Cheung, Thijs E. van Mens, Jeffrey I. Weitz]
Phase III clinical trials have shown that the NOACs, which include
dabigatran, rivaroxaban, apixaban and edoxaban, are at least as effective
as VKAs for treatment of patients with VTE and are associatedwith a re-
duced risk of major bleeding (relative risk [RR], 0.61; 95% CI, 0.45-0.83)
and intracranial bleeding (RR, 0.37; 95% CI, 0.21-0.68) [1,3,22–26].
Furthermore, rivaroxaban and apixaban can be administered in all-
oral regimens, which streamline therapy by obviating the need for
initial treatment with a parenteral anticoagulant. Therefore, NOACs
simplify VTE treatment.
For extended VTE treatment, dabigatran, rivaroxaban and apixaban
were superior to placebo for prevention of recurrence and were associ-
ated with low rates of major bleeding [2,3,27]. Both the prophylactic
and the treatment dose of apixaban (2.5 and 5 mg twice daily) were
compared with placebo for secondary VTE prevention. Both doses
reduced the risk of recurrence by a similar extent. Although rates of
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non-major bleeding with the lower dose regimen [2]. When compared
with warfarin for extended VTE treatment, dabigatran had similar effi-
cacy but was associatedwith a 50% reduction in the rate of major bleed-
ing [27]. Therefore, NOACs are not only useful for initial VTE treatment,
but also are effective and safe for extended VTE treatment. Furthermore,
at least with apixaban, it is possible to lower the dose after an initial
course of full-dose therapy, thereby reducing the risk of bleeding
without compromising efficacy.
2.1. Unmet Clinical Needs and Knowledge Gaps
2.1.1. Prevention of VTE
Patients with cancer are at risk for VTE, particularly when they are
receiving treatment with chemotherapy or biological agents [28]. Pro-
phylactic nadroparin or semuloparin have been shown to lower this
risk in high-risk cancer patients [29,30]. However, the need for daily
subcutaneous injections has tempered enthusiasm for primary prophy-
laxis with heparin derivatives. With oral administration and a low risk
of bleeding, the role of the NOACs for primary prophylaxis in high-risk
cancer patients requires investigation.
2.1.2. Treatment of Acute VTE
The current standard of care for cancer-associated VTE is LMWH.
Cancer patients were under-represented in the phase III trials of
the NOACs for VTE treatment. Nonetheless, a meta-analysis of the
results in such patients suggests that the NOACs are at least as effec-
tive as VKAs [31]. Additional studies are needed to determine how
the NOACs compare with LMWH in patients with cancer-associated
VTE.
2.1.3. Optimizing Therapy with the NOACs
Limited information is available on the benefit-risk profile of NOACs
in patients at extremes of bodyweight because fewpatients under 50 kg
or over 150 kg were included in the trials. Likewise, it is unknown
whether the absorption of the NOACs is impaired after bariatric proce-
dures such as gastric banding or Roux-en-Y gastric bypass. In addition,
the benefit-risk profile of the NOACs in patients with a creatinine
clearance less than 30 ml/min is uncertain. Such information is needed
to increase the generalizability of use of the NOACs in the spectrum of
VTE patients.
2.1.4. Secondary VTE Prevention
The prophylactic dose of apixaban was as effective as the treatment
dose for secondary VTE prevention [2]. Whether the same is true with
the other NOACs deserves investigation.
2.1.5. Influence of NOACs on the Risk of PTS
The risk of PTS in DVT patients treated with NOACs is unknown. Be-
cause of their more predictable anticoagulant response, NOACs could
decrease the risk of PTS compared with VKAs. However, without the
anti-inflammatory effects of heparins, all-oral therapy with NOACs
could compromise early thrombus resolution. Additional studies are
needed to test these possibilities.
Although NOACs do not require monitoring and dose adjustment,
assessing their anticoagulant effect or determiningplasmadrug concen-
trations can be useful in patients who present with serious bleeding or
acute renal impairment, and in those taking concomitant medications
that may interact with the NOACs. The NOACs have variable effects on
global tests of coagulation, such as the prothrombin time and activated
partial thromboplastin time. Therefore, assays that measure drug levels
are needed. Thesemay include the dilute thrombin time or ecarin chro-
mogenic assay formeasurement of dabigatran concentrations, and anti-
factor Xa assays for determination of the levels of rivaroxaban, apixaban
and edoxaban. Ideally, these tests should be in point-of-care format to
simplify rapid clinical decision making.Consensus:
a. In cancer patients, there is a need for investigation into the role
of NOACs for both VTE treatment and for VTE prophylaxis in
high-risk patients.
b. The benefit-risk profiles of NOACs in special patient groups, such as
patients with extreme bodyweights, patients after bariatric surgery
and patients with a creatinine clearance below 30 ml/min, deserves
to further investigation
c. Studies are needed to determine the effect of NOACs on the
incidence of PTS.
d. To assess the anticoagulant status of patients taking NOACs, point-
of-care assays to measure drug concentrations are desirable.
IV. Direct coagulation inhibitors and contact activation inhibitors
[David Gailani, Helen Philippou, José W. Govers-Riemslag, Suzanne
Bleker]
3. Factor XI and Factor XII
Based on work with animal models [32,33] and epidemiologic data
[34], factor XI (FXI) and factor XII (FXII) are now targets for novel anti-
thrombotic agents. Work with rodents, rabbits and primates indicate
that contact activation contributes to thrombus propagation [32,33].
There is a particularly strong case for a role for FXI in venous thrombo-
embolism (VTE) and stroke in humans [34]. As FXII deficiency does not
cause abnormal hemostasis [35], and FXI deficiency is associated with
mild bleeding [36], agents targeting these proteins should cause less
bleeding than VKAs or NOACs. Several proteins and a few small mole-
cule inhibitors of FXII and FXI, or their active forms FXIIa and FXIa,
have undergone preclinical testing [37]. Second generation antisense
oligonucleotides (ASOs) that reduce FXI synthesis have been studied
in humans [38,39]. Büller et al. compared ASO-mediated reduction of
plasma FXI with enoxaparin for thromboprophylaxis in patients under-
going total knee arthroplasty [39]. The highest ASO dose tested reduced
plasma FXI levels to ~20% of normal, with some patients having nearly
undetectable levels. This group had a markedly lower rate of radio-
graphically detected DVT (4%) than that in the enoxaparin controls
(30%). Interestingly, the few clots that formed in the high-dose ASO
group were very small, suggesting FXI contributes at an early stage of
thrombus growth. This challenges the prevailing notion that tissue fac-
tor is the major initiator and driver of VTE. Despite reduced FXI levels,
ASO-treated patients did not bleed excessively during surgery, and
overall bleeding rates were low in both ASO- and enoxaparin-treated
patients, consistent with the prediction that targeting the contact
pathway will have limited impact on hemostasis.
Based on the encouraging results from this primary prevention trial,
workshop participants felt that a phase 3 trial targeting FXI as secondary
prevention for VTE should be organized. While the ASO-based strategy
could be employed, an oral agent would be preferable. FXIa inhibitors
for parenteral administration are entering phase 1 testing, but oral
agents are still under development. Given the on-going debate regard-
ing the optimal duration of therapy for unprovoked VTE [40,41], it was
felt that there is a need for effective drugs with superior safety profiles
to VKAs andNOACs for long-term treatment. Therewas also enthusiasm
for a primary prevention trial using FXIa or FXIIa inhibitors for stroke
prevention in patients with atrial fibrillation. It should be possible to
superimpose such therapy on standard-of-care without significantly
increasing bleeding risk. Patients with severe FXI deficiency with atrial
fibrillation tolerate warfarin therapy (target INR 2.0 and 2.5) and
FXI-deficient patients have been placed on aspirin and clopidogrel
post-myocardial infarction [42].
Members of the workshop felt that contact activation inhibitors
should be tested in cancer patients to prevent VTE. Many of these
patients are at high risk for both thrombosis and bleeding, so an anti-
thrombotic agent that does not compromise hemostasis would be
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tients with chronic indwelling catheters for venous access or dialysis
to prevent catheter occlusion or catheter-associated thrombosis. In sup-
port of this, in recent studies, reducing FXII or FXI levels prolonged the
time to occlusion of catheters inserted into rabbit jugular veins [43].
Contact activation inhibitorsmay turn out to beuseful in a variety of set-
tingswhere blood comes into contactwith artificial surfaces. Contact ac-
tivation is triggered during cardiopulmonary bypass and extracorporeal
membrane oxygenation. The recent demonstration that an anti-FXIIa
antibody was comparable to heparin in its ability to prevent thrombus
formation in rabbits attached to a pediatric ECMO circuit supports the
notion that contact activation is a driver of thrombosis in extracorporeal
circuits [44]. Given the poor performance of dabigatran in a trial of pa-
tients with mechanical heart valves, VKAs remains the only oral agents
available for long-term treatment in this setting [45]. While the contri-
bution of the contact system to thrombosis associated with artificial
valves is not clear, materials used in heart valves should be tested for
their ability to induce contact activation.
As a long-term goal, we need to establish the roles of FXII and FXI in
different clinical scenarios to identify which target is best for various
indications. In general, FXI may contribute to thrombosis through two
pathways; contact activation and thrombin-mediated feedback activa-
tion of the intrinsic pathway [37]. However, FXIIa may contribute to
thrombosis not only by activating FXIa, but through FXI-independent
effects on fibrin clot stability [46]. Furthermore, FXIIa inhibition may
more effectively limit prekallikrein activation, and be a better anti-
inflammatory agent than FXIa inhibitors. The main safety concern
with FXIa inhibitors relates to the bleeding diathesis that can occur
with severe FXI deficiency. A concern raised with targeting FXII is that
it appears to be involved in processes other than thrombus formation.
FXIIa inhibitors could, for example, block the contribution of contact
activation to fibrinolysis [47,48]. However, there are other more
potent activators of fibrinolysis in blood, and it is not clear that loss of
FXIIa activity would produce a clinically significant fibrinolytic defect.
Inhibition of FXIIa leads to dose-dependent prevention of clot formation
[44].
Finally, we discussed the optimal levels of inhibition for FXI or FXII.
Hypothetically, complete inhibition of either target would be associated
with relatively few side effects, but there are concerns. Complete neu-
tralization of FXI could produce a bleeding diathesis similar to severe
congenital FXI deficiency [36,42].While the intracranial, retroperitoneal
and gastrointestinal bleeding events that complicate therapywith VKAs
or NOACs are unlikely to occur with FXI inhibitors (even with complete
inhibition), there could be problemswithmucosal bleeding, particularly
in menstruating woman. Based on ASO data from humans and non-
human primates [38,49,50], reducing FXI activity to ~20% of normal
may strike a reasonable balance between efficacy and bleeding risk.
For a FXII inhibitor, there was concern regarding the epidemiologic
data indicating an inverse relationship between plasma FXII level and
ischemic heart disease [51,52]. Interestingly, while the correlation was
apparent in two large studies for levels within the broad normal
range, patients with severe FXII deficiency were not at higher risk
for cardiac disease [52]. Thus, it may be best to have near complete
inhibition of FXII to produce an antithrombotic effect.
As we are able to progress towards contact pathway inhibition, it is
apparent that we are now entering an era where anticoagulant efficacy
may be achieved without the need to balance the induced risk of
bleeding associated with other anticoagulant targets.
Consensus:
a. FXI is a potential factor to inhibit for secondary VTE prevention
b. Phase 3 studies are needed to further investigate the role of inhibi-
tion of the contact pathway for secondary VTE prevention
c. The utility of inhibition of the contact pathway in patients with
catheters or cancer deserves investigationd. Role of FXII or contact activation in VTE, cardiopulmonary bypass or
mechanical valves needs to be determined
e. The optimal FXI or FXII level required to attenuate thrombosis needs
to be established
f. FXII has multiple functions including possibly playing a role in fibri-
nolysis in circumstances of low concentrations of tPA or uPA.
Whether FXII plays a role in fibrinolysis in vivo remains to be
established.. If FXII does play a role in fibrinolysis then FXII inhibitors
should be used in prophylactic settings.
g. Oral inhibitors of the contact system are preferred over parenteral
agents
V. Conservative management of the patient with PTS
[Arina J. ten Cate-Hoek, Annemieke C. Bouman]
PTS occurs in up to 50% of patientswith deep-vein thrombosis (DVT)
[53–55]. PTS decreases quality of life and can lead to chronic ulcers, and
its management is costly for the healthcare system [54]. Extensive DVT,
recurrent ipsilateral DVT and inadequate early anticoagulation are risk
factors for PTS [56,57]. Although studies suggested that early application
of elastic compression stockings (ECS) reduced the risk of PTS [53,58],
their effectiveness has been called into question by the results of a re-
cent randomized, placebo-controlled trial that showed that compared
with sham stockings, ECS did not prevent PTS [59].
The most important drawback for research and progress in clinical
care has been the limited correlation between the available diagnostic
clinical scales [60]. There are no dedicated prediction scores that incor-
porate clinical signs as well as established risk factors for PTS. The
Villalta score has been branded as the preferred diagnostic tool by the
International Society on Thrombosis and Haemostasis (ISTH) [61].
There is however still a need to improve the diagnostic accuracy and
the predictive quality of the Villalta score. It has been suggested to use
the Villalta score together with a disease specific quality of life score,
the Veines-Qol/Sym as the gold standard for the diagnosis of PTS [62].
It was discussed that itmight bemore efficient to add distinctive and
currentlymissing items such as venous claudication to the Villalta score.
Additional items suggested included impaired ankle movement, leg cir-
cumference, thrombus extent and biomarkers for PTS. For the late stage
follow-up and assessment of clinical change, there is a need to improve
the sensitivity to clinical change especially with respect to ulceration.
Workshop participants felt thatmore evidence is needed on the pre-
ventive qualities of compression therapy. The relevance of compression
therapy for thrombus resolution and its influence on inflammation, and
the consequences on PTS incidence should be further elucidated.
For the (conservative) treatment of PTS, more research into the
relevance of compression therapy as a mechanistic component for
edema reduction is needed. For the question as towhether compression
therapy can be of value for the prevention of PTS, the items that should
be addressed were discussed and it was felt that further studies are
needed on the value of compression (inelastic or elastic compression),
the timing of compression (time to compression, optimal duration of
compression), and issues surrounding compliance with therapy. (DCE,
education, assisting devices).
Both for the prevention and treatment of PTS, pharmacological treat-
ment such as drugs that increase the vascular integrity, veno-active
drugs (VADs), statins, heparins, and anti-inflammatory drugs should
be evaluated. Also, NOACs as a potential option for PTS prevention
should be investigated. Concern was expressed that pharmacological
therapy should not undermine compression therapy.
Biomarkers of inflammation and endothelial activation need to be
investigated more rigorously and endothelial activation and permeabil-
ity were perceived as an important pathway for subsequent inflamma-
tory processes in the perivascular space.
Oneof the obstacles in advancing PTS research is the lack of an objec-
tive diagnostic strategy for establishing the diagnosis of PTS. Until now
radiological vein wall abnormalities and valvular abnormalities only
show a poor association with clinical symptoms of PTS. With the
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of thrombus resolution and associated inflammatory processes of the
vein wall in the acute phase may be better visualised and may aid the
diagnostic procedure.
a. More evidence is needed about compression therapy
b. Focus should be on pharmacological therapy, but should not under-
mine the compression therapy
c. NOACs as a potential option for PTS prevention should be investigated
d. Separate prediction scores are needed for prevention and treatment
phase, including clinical scores and biomarkers
4. Proposal for Future Research Directions
The pleiotropic effects of statins need further research both for the
long-term prevention of recurrent VTE, as well as for its possible miti-
gating effect on the inflammatory response associated with thrombus
resolution and subsequent PTS.
Appropriate animal models of VTE and PTS are needed that incorpo-
rate processes of ageing and inflammation to further study thrombosis-
inflammation-crosstalk and to better understand the pathophysiology
of both primary and recurrent VTE and PTS.
There is no place for aspirin as secondary preventive treatment
except for specific patient categories such as patients with certain
solid tumours. This application needs further study.
Further studies should be planned to assess alternative anticoagu-
lant treatment modalities that inhibit the contact pathway i.e. at the
level of FXI or FXII, which may attenuate the risk of bleeding.
More research is needed for the assessment of preventive and ther-
apeutic qualities of compression therapy in VTE. The diagnostic proce-
dure needs adaptation and further evaluation. The potential role of
VADs, but also of statins, heparins and anti-inflammatory drugs, for
the prevention of PTS needs to be elucidated.
5. Significance of Increased Research
There are unmet needs concerning the non-invasive management
for both (recurrent) VTE and PTS. Reduction of bleeding events associat-
ed with anticoagulant treatment will lower the burden of disease and
make anticoagulant treatment more accessible for patients at high risk
for both VTE and bleeding. A definite target population in need of
improved anticoagulant treatment is the population of patients with
cancer. Also, long-term anticoagulant treatment for prevention of recur-
rent VTE will be easier to implement with agents that attenuate throm-
bosis without affecting hemostatsis. The study of drugs such as aspirin
and statins currently in use for other indications and thus directly avail-
able may expedite the process. Basic research into the mechanisms of
coagulation and inflammation may lead to the development of other
more favorable forms of antithrombotic treatment. Prevention of recur-
rent VTE will decrease the morbidity associated with PTS. Localized
processes of endothelial cell adhesion, and inflammation associated
with thrombosis need to be unraveled to optimize prevention and
treatment of VTE and its complications.
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